Physiomics PLC Disclosure of Large Pharma partner Merck & Co (0307W)
November 04 2014 - 1:01AM
UK Regulatory
TIDMPYC
RNS Number : 0307W
Physiomics PLC
04 November 2014
Physiomics plc
("Physiomics") or ("the Company")
Disclosure of Large Pharma partner Merck & Co.
Physiomics plc (AIM: PYC), the Oxford, UK based systems biology
company, is delighted to announce that Merck & Co., a top 5
pharmaceutical company, has disclosed that it is a customer of
Physiomics. Merck & Co. published a paper in CPT:
Pharmacometrics and Systems Biology (part of Nature Group) in which
Virtual Tumour was specified as a technology which had helped their
decision-making process.
The paper can be accessed at:
http://www.nature.com/psp/journal/v3/n10/full/psp201440a.html
Dr Mark Chadwick, CEO of Physiomics, commented:
"We are extremely pleased to be able to reveal the name of one
of our large pharma customers. Typically, customer names are not
disclosed for individual collaboration announcements due to
confidentiality concerns. This publication is the result of a
number of successful projects which have built trust between
Physiomics and Merck & Co. We look forward to continuing this
relationship in future."
Enquiries:
Physiomics plc
Dr Mark Chadwick, CEO
+44 (0)1865 784 980
WH Ireland Limited (broker/nomad)
Katy Mitchell
+44 (0) 161 832 2174
About Physiomics plc
Physiomics (AIM:PYC) is a computational systems biology services
company applying simulations of cell behaviour to drug development
to reduce the high attrition rates of clinical trials. 80-90 per
cent of all clinical drug candidates fail to reach the market and
estimates show that an overall ten per cent improvement in success
rates could reduce the cost of one drug's development by as much as
$242 million, from the current estimate of around $800 million(1)
.
Physiomics develops computational systems biology models to
predict and understand cancer drug efficacy from pre-clinical
research to clinical development. Physiomics has created detailed
mathematical models incorporating the most important molecular
events taking place during the human cell cycle and apoptosis
processes. The company's SystemCell(R) technology enables the
simulation of populations of "virtual cells". The company has also
developed a "Virtual Tumour" model to simulate the effect of
anti-cancer drugs on tumour growth. The models are used to optimise
compound design and to design drug schedules and combination
therapies.
Physiomics, based in Oxford, UK, was founded in 2001, and
floated on AIM in 2004. For further information, please visit
www.physiomics-plc.com
SystemCell(R) is a registered trademark of Physiomics plc
(1) Tufts Centre Impact Report 2002
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCEAKFDEADLFFF
Physiomics (LSE:PYC)
Historical Stock Chart
From Apr 2024 to May 2024
Physiomics (LSE:PYC)
Historical Stock Chart
From May 2023 to May 2024